Subtyping of circulating exosome-bound amyloid ? reflects brain plaque deposition

Abstract

Despite intense interests in developing blood measurements of Alzheimer’s disease (AD), the progress has been confounded by limited sensitivity and poor correlation to brain pathology. Here, we present a dedicated analytical platform for measuring different populations of circulating amyloid ? (A?) proteins – exosome-bound vs. unbound – directly from blood. The technology, termed amplified plasmonic exosome (APEX), leverages in situ enzymatic conversion of localized optical deposits and double-layered plasmonic nanostructures to enable sensitive, multiplexed population analysis. It demonstrates superior sensitivity (~200 exosomes), and enables diverse target co-localization in exosomes. Employing the platform, we find that prefibrillar A? aggregates preferentially bind with exosomes. We thus define a population of A? as exosome-bound (A?42+ CD63+) and measure its abundance directly from AD and control blood samples. As compared to the unbound or total circulating A?, the exosome-bound A? measurement could better reflect PET imaging of brain amyloid plaques and differentiate various clinical groups. © 2019, The Author(s).